Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Nancy L. Bartlett(Washington University in St. Louis), Marco Picardi(Federico II University Hospital), Árpád Illés(University of Debrecen), Tatyana Feldman(Hackensack University Medical Center), Andrea Gallamini(Centre Antoine Lacassagne), Kerry J. Savage(Spinal Cord Injury BC), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Joseph M. Connors, Rachael Liu(Takeda (United States)), Monika Długosz‐Danecka(National Institute of Oncology), Keenan Fenton(The Christie NHS Foundation Trust), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Radhakrishnan Ramchandren(The Christie NHS Foundation Trust), Jan Walewski(The Maria Sklodowska-Curie National Research Institute of Oncology), Stephen M. Ansell(Mayo Clinic), Ranjana H. Advani(Stanford Medicine), Piotr Smolewski(Medical University of Lodz), Martin Hutchings(University of Copenhagen), Anas Younes(Intercept Pharmaceuticals (United States)), Andres Forero-Torres(University of Alabama at Birmingham), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Won-Seog Kim(Samsung Medical Center), Sergey Alekseev(Institute of Oncology NN Petrov), David J. Straus(Memorial Sloan Kettering Cancer Center), Harry Miao(Takeda (United States)), John Radford(Manchester Academic Health Science Centre)
Cited by 1
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k